Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.

231.83 2.20 −0.94%
Market cap
$31.3B
P/E
39.5×
Fwd P/E
39.6×
Dividend yield
—
F-score
6/9
Altman Z
7.30
Beneish M
−1.95
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
2 5 2 2 4 3 3 5 5 6
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 163.12
P/S ratio
70.13 132.79 97.91 57.26 30.32 23.79 27.40 13.32 13.36 14.03
Altman Z-Score
3.22 28.92 12.72 5.20 1.92 2.14 2.30 1.84 2.90 7.30
Altman Z″-Score (non-manufacturers)
(0.91) 8.26 (0.09) (2.40) (1.67) (2.17) (4.01) (3.07) (2.60) (0.11)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 580.47 0.00 111.94
P/Operating CF
(42.22) (115.87) (48.74) (64.21) (121.36) (133.79) (215.38) (817.18) (317.31) 318.51
Beneish M-Score
(2.03) (2.25) (3.71) (1.52) 3.21 (3.03) (3.07) (2.66) (2.50) (1.95)
P/B ratio
3.59 6.76 5.63 8.75 14.71 34.15 0.00 0.00 447.73 66.01
Price to Tangible BV
3.59 6.76 5.63 8.75 14.71 34.15 0.00 0.00 447.73 66.01
EV/Sales
60.02 114.32 83.83 51.53 26.91 21.71 26.27 12.54 12.62 13.51
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 90.08
EV/Operating CF
(9.20) (26.85) (11.16) (40.67) (21.56) (28.56) (50.34) 220.14 (3,412.86) 95.77
EV/FCF
(7.60) (21.11) (9.11) (27.05) (19.35) (25.52) (44.43) 546.65 (666.08) 107.85
Quick Ratio
4.94 11.96 6.14 4.48 4.23 3.79 3.16 2.86 2.61 2.51
Current Ratio
5.10 12.23 6.69 4.87 4.47 4.04 3.51 3.08 2.78 2.76
Net Debt/EBITDA
1.16 3.40 1.32 1.42 2.23 2.84 1.59 6.22 13.89 (3.41)
Debt/Assets
11.88% 1.50% 1.91% 11.52% 5.61% 18.55% 28.68% 26.65% 24.17% 20.29%
Debt/Equity
0.16 0.02 0.02 0.19 0.19 1.15 (6.43) (4.63) 15.27 1.28
Asset Turnover
0.04 0.06 0.04 0.11 0.17 0.24 0.29 0.50 0.56 0.81
Operating CF/Net income
0.75 0.78 0.74 0.31 0.72 0.75 0.48 (0.24) 0.03 1.67
Capex/Depreciation
(4.27) (8.76) (8.32) (2.58) (0.95) (0.85) (1.62) (1.15) (0.60) (1.05)
Interest Coverage
(51.11) (40.87) (28.09) (28.47) (9.80) (4.95) (5.03) (2.33) (1.25) 1.99
ROE
(37.54%) (36.54%) (49.63%) (64.66%) (69.92%) (106.31%) (526.14%) 232.40% 362.29% 73.28%
ROA
(30.96%) (30.14%) (42.67%) (44.64%) (29.58%) (24.19%) (31.47%) (11.94%) (6.89%) 6.82%
ROIC
(59.85%) (295.38%) (205.47%) (328.88%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(62.64%) (27.23%) (56.75%) (49.55%) (34.41%) (32.61%) (46.21%) (17.33%) (10.65%) 10.13%
Average Days of Receivables
180.60 138.03 91.41 71.44 446.14 85.85 83.72 65.44 65.80 76.42
Research and Development Expense of Revenue
810.86% 434.46% 674.72% 298.12% 132.86% 93.83% 85.12% 54.94% 50.09% 35.54%
Selling, General and Administrative Expense of Revenue
189.47% 221.73% 510.44% 217.98% 119.39% 73.51% 74.29% 43.52% 43.39% 32.60%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
160.16% 103.23% 210.59% 79.56% 28.38% 19.63% 22.23% 12.12% 12.10% 9.38%
Graham Net Nets
0.10 0.13 0.13 0.06 0.02 (0.01) (0.04) (0.04) (0.03) 0.00
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 16.49 11.84 0.00 18.18
Earnings Yield
(12.40%) (4.10%) (10.37%) (7.07%) (5.73%) (4.25%) (3.98%) (1.81%) (0.92%) 0.61%
Free Cash Flow Yield
(11.26%) (4.08%) (9.40%) (3.33%) (4.59%) (3.57%) (2.16%) 0.17% (0.14%) 0.89%
Revenue per Share
0.55 0.99 0.74 2.01 4.29 7.13 8.53 14.64 17.61 28.35
Operating CF per Share
(3.59) (4.23) (5.59) (2.55) (5.35) (5.42) (4.45) 0.83 (0.07) 4.00
Capex per Share
(0.75) (1.15) (1.26) (1.28) (0.61) (0.64) (0.59) (0.50) (0.27) (0.45)
Free Cash Flow per Share
(4.35) (5.38) (6.85) (3.83) (5.96) (6.06) (5.04) 0.34 (0.33) 3.55
Cash per Share
7.32 18.67 10.78 14.06 16.30 20.56 18.02 19.53 21.11 22.20
Shareholders Equity per Share
10.75 19.51 12.94 13.17 8.84 4.97 (1.30) (1.77) 0.53 6.02
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
10.75 19.51 12.94 13.17 8.84 4.97 (1.30) (1.77) 0.53 6.02
Free Cash Flow
(372.26) (486.99) (689.50) (418.58) (685.32) (718.06) (613.33) 41.95 (42.59) 465.38
Working Capital
540.18 1,620.49 1,021.20 1,363.27 2,029.51 2,112.87 1,924.33 2,014.91 2,109.01 2,584.31
Capital Expenditures
(64.56) (104.21) (126.89) (140.16) (70.36) (76.37) (72.06) (62.21) (34.28) (58.70)
Net Current Asset Value
329.29 1,536.44 927.86 759.42 223.96 (246.52) (1,012.33) (1,067.83) (877.61) (126.49)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.07
Capex to Sales
1.37 1.16 1.69 0.64 0.14 0.09 0.07 0.03 0.02 0.02
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 103.86
Other line items
Depreciation/Fixed assets
0.13 0.07 0.05 0.13 0.16 0.18 0.08 0.10 0.11 0.11
Cash ROIC
(21.94%) (13.97%) (28.54%) (12.88%) (22.24%) (19.41%) (20.10%) 1.29% (1.12%) 9.89%
Accounts Receivable Turnover
2.98 3.14 2.84 7.12 1.53 2.11 4.75 6.46 6.13 6.28
Accounts Payable Turnover
0.00 0.00 0.04 0.46 1.53 2.24 1.97 4.04 4.49 6.68
Inventory Turnover
— — 0.05 0.62 1.19 1.73 1.57 2.85 3.86 8.46
Average Days of Payables
0.00 0.00 12,094.02 726.50 243.01 191.24 212.09 65.28 99.80 61.94
Days of Inventory on Hand
— — 4,875.04 820.65 351.67 224.93 278.83 104.82 88.62 44.28
Average Receivables
15.82 28.67 26.38 30.89 322.71 400.49 218.27 282.88 366.55 591.44
Average Payables
35.63 41.41 44.03 54.80 50.93 62.70 85.76 76.81 71.97 102.07
Average Inventory
— — 40.00 40.21 65.78 80.78 107.66 109.05 83.83 80.61
Average Assets
1,324.66 1,628.77 1,784.77 1,984.97 2,901.10 3,525.18 3,594.83 3,688.12 4,034.93 4,603.16
Average Common Equity
1,092.47 1,343.33 1,534.20 1,370.33 1,227.47 802.23 214.99 (189.43) (76.78) 428.13

Fold the line items

Columns are period end dates